Bansal Devendra, Atia Hassan, Al Badr Mashael, Nour Mohamed, Abdulmajeed Jazeel, Hasan Amal, Al-Hajri Noora, Ahmed Lina, Ibrahim Rumissa, Zamel Reham, Mohamed Almuthana, Pattalaparambil Hamad, Daraan Faisal, Chaudhry Adil, Oraby Sahar, El-Saleh Sahar, El-Shafie Sittana S, Al-Farsi Affra Faiz, Paul Jiji, Ismail Ahmed, Al-Romaihi Hamad Eid, Al-Thani Mohammed Hamad, Doi Suhail A R, Zughaier Susu M, Cyprian Farhan, Farag Elmobashar, Farooqui Habib Hasan
Health Protection and Communicable Disease Control, Ministry of Public Health, Doha P.O. Box 42, Qatar.
National Reference Laboratory, Ministry of Public Health, Doha P.O. Box 42, Qatar.
Vaccines (Basel). 2023 Feb 21;11(3):496. doi: 10.3390/vaccines11030496.
There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan-Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.
关于卡塔尔人群中mRNA疫苗和非mRNA疫苗抗体滴度的大小及长期持久性，血清流行病学证据有限。本研究旨在获取关于完成COVID-19初级疫苗接种方案的个体中抗S IgG抗体滴度及其动态变化的证据。共有300名男性参与者纳入我们的研究，他们接种了以下任何一种疫苗：BNT162b2/Comirnaty、mRNA-1273、ChAdOx1-S/Covishield、COVID-19疫苗杨森/强生，或BBIBP-CorV或科维福。所有血清样本均通过化学发光微粒子免疫分析（CMIA）进行检测，以定量测定针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白S1亚基受体结合域（RBD）的IgG抗体。还测定了针对SARS-CoV-2核衣壳的抗体（SARS-CoV-2 N蛋白IgG）。采用Kaplan-Meier生存曲线比较从初级疫苗接种方案最后一剂接种时间到mRNA疫苗和非mRNA疫苗抗S IgG抗体滴度降至最低四分位数（收集的值范围）的时间。接种mRNA疫苗的参与者抗S IgG抗体滴度中位数较高。接种mRNA-1273疫苗的参与者抗S抗体水平中位数最高，为13720.9 AU/mL（四分位间距6426.5至30185.6 AU/mL），其次是BNT162b2（中位数7570.9 AU/mL；四分位间距3757.9至16577.4 AU/mL）；而未接种mRNA疫苗参与者的抗S抗体滴度中位数为3759.7 AU/mL（四分位间距2059.7 - 5693.5 AU/mL）。非mRNA疫苗接种者和辉瑞疫苗接种者达到最低四分位数的中位时间分别为3.53个月（四分位间距2.2 - 4.5个月）和7.63个月（四分位间距6.3 - 8.4个月）。然而，超过50%的莫德纳疫苗接种者在随访期结束时未达到最低四分位数。在为接受不同类型（mRNA与非mRNA）疫苗及自然感染个体的初级疫苗全程接种后中和活性的持久性及因此预防感染的决策提供信息时，应考虑这些关于抗S IgG抗体滴度的证据。
